Researchers optimistic radioactive lead can beat cancer

Atomic medicine has "fantastic potential" for fighting deadly, difficult to treat cancers, the head of French nuclear giant Areva's medical said.
"We are interested in tumours against which the current therapeutic arsenal is very limited -- like ovarian, gastric and pancreatic cancers -- where the needs are huge and patients are waiting," explained Areva Med chief Patrick Bourdet.
Based in a Maryland suburb of the US capital, not far from the National Institutes of Health, Areva Med is pitting its hopes on a rare radioactive isotope that may be capable of selectively annihilating cancer cells.
This new weapon against these aggressive cancers is a variety of lead: the isotope Pb 212. It is extremely rare, extracted from an equally rare metal called thorium.

Only the few major nuclear powers have stocks of the radioactive metal -- France, being one of them, with a considerable cache, Bourdet told AFP.
France's stock can be traced back half a decade to its nuclear subsidiary.

At that time, the Commissary of Atomic Energy, or CEA, a government-funded research group, decided to hold on to thorium after it extracted uranium -- which has become the principal material used in nuclear power plants.
In 2003, researchers had the idea of extracting the isotope Pb 212 from the thorium, with Areva's scientists among them, looking in part for possible applications against cancer.

Convinced of the great medical potential of this isotope, Areva created its medical affiliate in 2009 in the United States, which, since then, hasn't stopped growing.